|An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells|
D Rohle, J Popovici-Muller, N Palaskas, S Turcan, C Grommes, ...
Science 340 (6132), 626-630, 2013
|Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma|
J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ...
Nature communications 5 (1), 1-15, 2014
|Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma|
S Hu-Lieskovan, S Mok, BH Moreno, J Tsoi, L Robert, L Goedert, ...
Science translational medicine 7 (279), 279ra41-279ra41, 2015
|CTLA4 blockade broadens the peripheral T-cell receptor repertoire|
L Robert, J Tsoi, X Wang, R Emerson, B Homet, T Chodon, S Mok, ...
Clinical Cancer Research 20 (9), 2424-2432, 2014
|Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress|
J Tsoi, L Robert, K Paraiso, C Galvan, KM Sheu, J Lay, DJL Wong, M Atefi, ...
Cancer cell 33 (5), 890-904. e5, 2018
|Genetic mechanisms of immune evasion in colorectal cancer|
CS Grasso, M Giannakis, DK Wells, T Hamada, XJ Mu, M Quist, JA Nowak, ...
Cancer discovery 8 (6), 730-749, 2018
|Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma|
A Ribas, D Lawrence, V Atkinson, S Agarwal, WH Miller, MS Carlino, ...
Nature medicine 25 (6), 936-940, 2019
|Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance|
Y Su, W Wei, L Robert, M Xue, J Tsoi, A Garcia-Diaz, BH Moreno, J Kim, ...
Proceedings of the National Academy of Sciences 114 (52), 13679-13684, 2017
|Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma|
DJL Wong, L Robert, MS Atefi, A Lassen, G Avarappatt, M Cerniglia, ...
Molecular cancer 13 (1), 1-15, 2014
|Immunotherapy resistance by inflammation-induced dedifferentiation|
A Mehta, YJ Kim, L Robert, J Tsoi, B Comin-Anduix, B Berent-Maoz, ...
Cancer discovery 8 (8), 935-943, 2018
|Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells|
BH Moreno, JM Zaretsky, A Garcia-Diaz, J Tsoi, G Parisi, L Robert, ...
Cancer immunology research 4 (10), 845-857, 2016
|Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma|
CS Grasso, J Tsoi, M Onyshchenko, G Abril-Rodriguez, ...
Cancer cell 38 (4), 500-515. e3, 2020
|A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab|
TS Nowicki, B Berent-Maoz, G Cheung-Lau, RR Huang, X Wang, J Tsoi, ...
Clinical Cancer Research 25 (7), 2096-2108, 2019
|Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition|
S Mok, J Tsoi, RC Koya, S Hu-Lieskovan, BL West, G Bollag, TG Graeber, ...
BMC cancer 15 (1), 1-10, 2015
|PAK4 inhibition improves PD-1 blockade immunotherapy|
G Abril-Rodriguez, DY Torrejon, W Liu, JM Zaretsky, TS Nowicki, J Tsoi, ...
Nature Cancer 1 (1), 46-58, 2020
|Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist|
G Parisi, JD Saco, FB Salazar, J Tsoi, P Krystofinski, C Puig-Saus, ...
Nature Communications 11 (1), 1-12, 2020
|Overcoming genetically based resistance mechanisms to PD-1 blockade|
DY Torrejon, G Abril-Rodriguez, AS Champhekar, J Tsoi, KM Campbell, ...
Cancer Discovery 10 (8), 1140-1157, 2020
|Precise T cell recognition programs designed by transcriptionally linking multiple receptors|
JZ Williams, GM Allen, D Shah, IS Sterin, KH Kim, VP Garcia, GE Shavey, ...
Science 370 (6520), 1099-1104, 2020
|Applications of a planar electrochemiluminescence platform to support regulated studies of macromolecules: benefits and limitations in assay range|
T Thway, C Macaraeg, D Calamba, V Patel, J Tsoi, M Ma, J Lee, ...
Journal of pharmaceutical and biomedical analysis 51 (3), 626-632, 2010
|A strategy for improving comparability across sites for ligand binding assays measuring therapeutic proteins|
CA Ray, L Zhou, J Tsoi, L Uy, J Gu, J Malella, D DeSimone, H Gunn, ...
Journal of pharmaceutical and biomedical analysis 53 (3), 729-734, 2010